Pediatric Axial Ewing Sarcoma: A Retrospective Population-Based Survival Analysis.
Journal
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
ISSN: 2474-7661
Titre abrégé: J Am Acad Orthop Surg Glob Res Rev
Pays: United States
ID NLM: 101724868
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
05
04
2024
accepted:
10
04
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
18
7
2024
Statut:
epublish
Résumé
Ewing sarcomas of the axial skeleton represent a notable challenge for clinicians because of their aggressive presentation and tendency to obstruct neurovascular structures; however, little data exist regarding axial tumors in children. This study is the first population-based analysis assessing treatment regimens for axial Ewing sarcomas and their effects on cancer-specific survival and overall survival (OS). Data from 2004 to 2019 were collected for all patients aged 1 to 24 years from the Surveillance, Epidemiology, and End Results (SEER) database. Primary groups included pelvic tumors, thoracic tumors, and vertebral tumors. Chi-squared and Kaplan-Meier tests were used to assess associations between demographic variables, clinical and treatment characteristics, and patient survival. Pelvic tumors were most common, and 49.7% received chemotherapy/radiation. Vertebral tumors were least common, and 56.7% received chemotherapy/surgery/radiation. 53.5% of thoracic tumors received chemotherapy/surgery. Surgery was most common for thoracic tumors (80.2%) and rare for pelvic tumors (38.9%). Radiation therapy was most common for vertebral tumors (83.6%) and least common for thoracic tumors (36.0%). Pelvic tumors exhibited the lowest OS (1-year, 5-year, and 10-year OS: 96%, 70%, and 59%), followed by thoracic tumors (1-year, 5-year, and 10-year OS: 97%, 79%, and 66%) and vertebral tumors (1-year, 5-year, and 10-year OS: 92%, 77%, and 68%). This study underpins the importance of both early detection and chemotherapy-based multimodal therapy in the treatment of axial Ewing sarcoma in a pediatric population. A comparatively large decline in OS was observed between 5 and 10 years for patients with thoracic tumors, and this cohort's 10-year OS has not improved when compared with a similar SEER cohort from 1973 to 2011. Despite a growing body of research supporting definitive radiation therapy, a notable portion of patients with pelvic Ewing sarcoma did not receive radiation, representing an unmet need for this population.
Identifiants
pubmed: 39024656
doi: 10.5435/JAAOSGlobal-D-24-00130
pii: 01979360-202407000-00015
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons.
Références
Zöllner SK, Amatruda JF, Bauer S, et al.: Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med 2021;10:1685.
Sbaraglia M, Righi A, Gambarotti M, Dei Tos AP: Ewing sarcoma and Ewing-like tumors. Virchows Archiv: Int J Pathol 2020;476:109-119.
Esiashvili N, Goodman M, Marcus RB Jr: Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 2008;30:425-430.
Meazza C, Luksch R, Luzzati A: Managing axial bone sarcomas in childhood. Expert Rev Anticancer Ther 2021;21:747-764.
Hesla AC, Papakonstantinou A, Tsagkozis P: Current status of management and outcome for patients with ewing sarcoma. Cancers (Basel) 2021;13:1202.
Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP: Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: An analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009;115:3526-3536.
Muratori F, Totti F, Cuomo P, et al.: Multimodal treatment in pelvic ewing sarcoma: A prognostic factor analysis. Surg Technol Int 2019;34:489-496.
Guder WK, Hardes J, Nottrott M, Steffen AJ, Dirksen U, Streitbürger A: Pelvic ewing sarcoma: A retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center. J Orthop Surg Res 2020;15:534.
About the SEER program. Available at: https://seer.cancer.gov/about/. Accessed December 01, 2022.
Hu S, Zhang W, Guo Q, et al.: Prognosis and survival analysis of 922,317 lung cancer patients from the US based on the most recent data from the SEER database (april 15, 2021). Int J Gen Med 2021;14:9567-9588.
Cole S, Gianferante DM, Zhu B, Mirabello L: Osteosarcoma: A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer 2022;128:2107-2118.
Ingram DD, Franco SJ: 2013 NCHS urban-rural classification scheme for counties. Vital Health Statistics Ser 2, Data Eval Methods Res 2 2014:1-73.
Burchill SA: Ewing's sarcoma: Diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 2003;56:96-102.
Gaspar N, Hawkins DS, Dirksen U, et al.: Ewing sarcoma: Current management and future approaches through collaboration. J Clin Oncol 2015;33:3036-3046.
Denbo JW, Shannon Orr W, Wu Y, et al.: Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: A single-institution experience. Ann Surg Oncol 2012;19:3809-3815.
Brennan B, Kirton L, Marec-Bérard P, et al.: Comparison of two chemotherapy regimens in patients with newly diagnosed ewing sarcoma (EE2012): An open-label, randomised, phase 3 trial. Lancet 2022;400:1513-1521.
Dunst J, Schuck A: Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer 2004;42:465-470.
Ilaslan H, Sundaram M, Unni KK, Dekutoski MB: Primary Ewing's sarcoma of the vertebral column. Skeletal Radiol 2004;33:506-513.
Sharafuddin MJ, Haddad FS, Hitchon PW, Haddad SF, el-Khoury GY: Treatment options in primary ewing's sarcoma of the spine: Report of seven cases and review of the literature. Neurosurgery 1992;30:610-619.
Hesla AC, Bruland ØS, Jebsen N, Styring E, Eriksson S, Tsagozis P: Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years. J Bone Oncol 2019;14:100216.
Charest-Morin R, Dirks MS, Patel S, et al.: Ewing sarcoma of the spine: Prognostic variables for survival and local control in surgically treated patients. Spine 2018;43:622-629.
Indelicato DJ, Vega RBM, Viviers E, et al.: Modern therapy for chest wall ewing sarcoma: An update of the university of Florida experience. Int J Radiat Oncol Biol Phys 2022;113:345-354.
Applebaum MA, Worch J, Matthay KK, et al.: Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011;117:3027-3032.
Paulussen M, Fröhlich B, Jürgens H: Ewing tumour: Incidence, prognosis and treatment options. Paediatr Drugs 2001;3:899-913.
Gladish GW, Sabloff BM, Munden RF, Truong MT, Erasmus JJ, Chasen MH: Primary thoracic sarcomas. Radiographics 2002;22:621-637.
Seitz G, Urla C, Sparber-Sauer M, et al.: Treatment and outcome of patients with thoracic tumors of the ewing sarcoma family: A report from the cooperative weichteilsarkom studiengruppe CWS-81, -86, -91, -96, and -2002P trials. Pediatr Blood Cancer 2019;66:e27537.
Provost B, Missenard G, Pricopi C, et al.: Ewing sarcoma of the chest wall: Prognostic factors of multimodal therapy including en bloc resection. Ann Thorac Surg 2018;106:207-213.
Bedetti B, Wiebe K, Ranft A, et al.: Local control in ewing sarcoma of the chest wall: Results of the EURO-EWING 99 trial. Ann Surg Oncol 2015;22:2853-2859.
Harris CJ, Helenowski I, Murphy AJ, et al.: Implications of tumor characteristics and treatment modality on local recurrence and functional outcomes in children with chest wall sarcoma: A pediatric surgical Oncology research collaborative study. Ann Surg 2022;276:e969-e975.
Jacobs AJ, Fishbein J, Levy CF, Glick RD: Chest wall ewing sarcoma: A population-based analysis. J Surg Res 2016;204:475-480.
Indelicato DJ, Vega RBM, Viviers E, et al.: Modern therapy for spinal and paraspinal ewing sarcoma: An update of the university of Florida experience. Int J Radiat Oncol Biol Phys 2022;113:161-165.
Brown JM, Rakoczy K, Tokson JH, Jones KB, Groundland JS: Ewing sarcoma of the pelvis: Clinical features and overall survival<sup/>. Cancer Treat Res Commun 2022;33:100634.
Rödl RW, Hoffmann C, Gosheger G, Leidinger B, Jürgens H, Winkelmann W: Ewing's sarcoma of the pelvis: Combined surgery and radiotherapy treatment. J Surg Oncol 2003;83:154-160.
Ahmed SK, Robinson SI, Arndt CAS, et al.: Pelvis Ewing sarcoma: Local control and survival in the modern era. Pediatr Blood Cancer 2017;64.
Akagunduz OO, Kamer SA, Kececi B, et al.: The role of radiotherapy in local control of nonextremity Ewing sarcomas. Tumori 2016;102:162-167.
Ng VY, Jones R, Bompadre V, Louie P, Punt S, Conrad EU: 3rd: The effect of surgery with radiation on pelvic Ewing sarcoma survival. J Surg Oncol 2015;112:861-865.
Lex JR, Kurisunkal V, Kaneuchi Y, et al.: Pelvic Ewing sarcoma: Should all patients receive pre-operative radiotherapy, or should it be delivered selectively?. Eur J Surg Oncol 2021;47:2618-2626.
Dramis A, Grimer RJ, Malizos K, Tillman RM, Jeys L, Carter LR: Non-metastatic pelvic ewing's sarcoma: Oncologic outcomes and evaluation of prognostic factors. Acta Orthop Belg 2016;82:216-221.
Cotterill SJ, Ahrens S, Paulussen M, et al.: Prognostic factors in ewing's tumor of bone: Analysis of 975 patients from the European intergroup cooperative ewing's sarcoma study group. J Clin Oncol 2000;18:3108-3114.
Duchman KR, Gao Y, Miller BJ: Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 2015;39:189-195.